FOXP3 and type 1 diabetes mellitus: Although the exact process by which the protein treats T1D remains to be discovered, these findings validate the use of the autoantigen insulin as an ideal immunotherapy strategy in the treatment of diseases involving CD4+CD25+Foxp3+ Treg cells.